Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Income from Continuing Operations of 25116000.0 for Q3 2025, up 59.58% year-over-year from 15738914.2 in Q3 2024, and up 51.66% quarter-over-quarter from 51962000.0 in Q2 2025.
Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Income from Continuing Operations for 11 consecutive years, with 25116000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Income from Continuing Operations rose 59.58% year-over-year to 25116000.0; the TTM figure through Sep 2025 stood at 201526000.0 (up 7.44% YoY), while the FY2024 annual figure was 626090000.0, down 30.37% from the prior year.
- Income from Continuing Operations rose to 25116000.0 in Q3 2025 per EDIT's latest filing, from 51962000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 22185000.0 in Q4 2023 and bottomed at 4005050000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 444066263.16 across 5 years, with a median of 67606000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 3901.13% — and 2023, when it soared 92.91%.
- Editas Medicine's Income from Continuing Operations stood at 33717000.0 in 2021, then sank by 71.62% to 57865000.0 in 2022, then soared by 61.66% to 22185000.0 in 2023, then sank by 105.52% to 45595000.0 in 2024, then surged by 44.92% to 25116000.0 in 2025.
- Business Quant data shows EDIT's Income from Continuing Operations at 25116000.0 in Q3 2025, 51962000.0 in Q2 2025, and 78853000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -51.96 Mn |
| Mar 31, 2025 | -78.85 Mn |
| Dec 31, 2024 | -45.60 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -65.80 Mn |
| Dec 31, 2023 | -22.19 Mn |
| Sep 30, 2023 | -132.82 Mn |
| Jun 30, 2023 | -506.50 Mn |
| Mar 31, 2023 | -283.96 Mn |
| Dec 31, 2022 | -57.87 Mn |
| Sep 30, 2022 | -1.59 Bn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -4.01 Bn |
| Dec 31, 2021 | -33.72 Mn |
| Sep 30, 2021 | -67.50 Mn |
| Jun 30, 2021 | -130.67 Mn |
| Mar 31, 2021 | -100.10 Mn |
| Dec 31, 2020 | -58.99 Mn |